CMS Issues Rule to Promote Drug Price Transparency / by Joe Furia

Debbie Johnston, Senior Vice President of Policy Development

This week, the Centers for Medicare & Medicaid Services (CMS) unveiled a much anticipated  proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs. The rule would require drug manufacturers to include list prices in all direct-to-consumer television advertisements of prescription drugs and biological products for which Medicare or Medicaid reimbursement is available. The specific drugs that would require list price disclosure are those that are used for a 30-day regimen or for a typical course of treatment and for which the list price is greater than $35 per month.
 
AzHHA believes the escalating price of prescription drugs threatens the affordability of healthcare for all Arizonans, and we strongly support policy recommendations proposed by the Campaign for Sustainable Rx Pricing. The proposed rule by CMS is certainly a step in the right direction. Comments on the proposal will be accepted through December 17th. For more information, see the agency’s press release.